The Only Monthly Membership With a Positive ROI!
España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
The Only Monthly Membership With a Positive ROI!
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Comments
Close menu
Loading...
Veracyte
VCYT
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$23.70
-0.02
-0.08%
Pre-Market: Jul 26, 4:44 PM EDT
15 minutes delayed
Get Report
Comment
Q2 2024 Earnings in 8 days from now on Tue Aug 6th, after the market close
Veracyte (VCYT) Forecast
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Veracyte (NASDAQ:VCYT) Stock
Veracyte Stock (NASDAQ: VCYT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, June 25, 2024
3 Top-Ranked Efficient Stocks to Increase Your Portfolio Returns
Zacks
Tuesday, June 11, 2024
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
Benzinga Neuro
Monday, June 03, 2024
Veracyte Reports Research Using Afirma GRID T...
Benzinga Newsdesk
Thursday, May 23, 2024
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
Zacks
Wednesday, May 08, 2024
A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts
Benzinga Insights
Needham Maintains Buy on Veracyte, Lowers Pri...
Benzinga Newsdesk
Tuesday, May 07, 2024
Veracyte Q1 2024 GAAP EPS $(0.02) Beats $(0.1...
Benzinga Newsdesk
Veracyte Raises FY24 Revenue From $394M-$402M...
Benzinga Newsdesk
Monday, May 06, 2024
Veracyte Announces Data From 14 Studies Prese...
Benzinga Newsdesk
Monday, April 22, 2024
Veracyte's New Study Shows The Decipher Prost...
Benzinga Newsdesk
Tuesday, April 16, 2024
Veracyte Announces 9 Abstracts Reinforcing Th...
Benzinga Newsdesk
Monday, April 15, 2024
Goldman Sachs Maintains Buy on Veracyte, Lowe...
Benzinga Newsdesk
Thursday, February 29, 2024
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
Benzinga Neuro
Wednesday, February 28, 2024
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
Benzinga Neuro
Tuesday, February 27, 2024
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
Benzinga Neuro
Monday, February 26, 2024
Morgan Stanley Maintains Underweight on Verac...
Benzinga Newsdesk
Friday, February 23, 2024
Needham Maintains Buy on Veracyte, Raises Pri...
Benzinga Newsdesk
Thursday, February 22, 2024
Veracyte Sees FY24 Revenue $394M-$402M Vs $39...
Benzinga Newsdesk
Recap: Veracyte Q4 Earnings
Benzinga Insights
Veracyte Q4 2023 Adj EPS $0.05 Beats $(0.09) ...
Benzinga Newsdesk
Earnings Scheduled For February 22, 2024
Benzinga Insights
Wednesday, February 21, 2024
Earnings Outlook For Veracyte
Benzinga Insights
Thursday, December 28, 2023
Cathie Wood's Ark Invest Buys Over $92M Worth Of ProShares Bitcoin ETF, Sells Coinbase, Block And Palantir Shares
Benzinga Neuro
Wednesday, November 29, 2023
Clinical Validation Data Published In CHEST D...
Benzinga Newsdesk
Wednesday, November 22, 2023
Veracyte Announces Seven Posters Highlighting...
Benzinga Newsdesk
Friday, November 10, 2023
Morgan Stanley Maintains Underweight on Verac...
Benzinga Newsdesk
Wednesday, November 08, 2023
Needham Maintains Buy on Veracyte, Lowers Pri...
Benzinga Newsdesk
Veracyte Raises FY23 Revenue From $342M-$350M...
Benzinga Newsdesk
Tuesday, November 07, 2023
Veracyte: Q3 Earnings Insights
Benzinga Insights
Veracyte Q3 2023 Gaap EPS $(0.41) Misses $(0....
Benzinga Newsdesk
Veracyte Announces In Vitro Diagnostic Agreem...
Benzinga Newsdesk
Earnings Scheduled For November 7, 2023
Benzinga Insights
Monday, October 23, 2023
Goldman Sachs Maintains Buy on Veracyte, Lowe...
Benzinga Newsdesk
Friday, October 20, 2023
The Latest Analyst Ratings for Veracyte
Benzinga Insights
Goldman Sachs Maintains Buy on Veracyte, Lowe...
Benzinga Newsdesk
Thursday, October 12, 2023
New Data Presented At CHEST 2023 Demonstrate ...
Benzinga Newsdesk
Tuesday, October 10, 2023
Stephens & Co. Reiterates Overweight on Verac...
Benzinga Newsdesk
Wednesday, October 04, 2023
Veracyte Stock Is Volatile After-Hours - Here's Why
Ryan Gustafson
New Data From Phase 3 Trial Further Validate ...
Benzinga Newsdesk
Thursday, September 28, 2023
New Data Presented At The 2023 ATA Annual Mee...
Benzinga Newsdesk
Thursday, September 21, 2023
Veracyte Announces Novel Afirma-Based Finding...
Benzinga Newsdesk
Wednesday, September 06, 2023
Veracyte And Gustave Roussy Announce Collabor...
Benzinga Newsdesk
Tuesday, August 22, 2023
Veracyte Announces That Findings Published In JCO Precision Oncology Suggest Potential Of Decipher GRID-Derived Gene Signatures To Predict Treatment Response In Recurrent Prostate Cancer
Happy Mohamed
Wednesday, August 09, 2023
Morgan Stanley Maintains Underweight on Verac...
Benzinga Newsdesk
Needham Maintains Buy on Veracyte, Raises Pri...
Benzinga Newsdesk
Tuesday, August 08, 2023
Veracyte Raises FY23 Revenue Guidance From $3...
Benzinga Newsdesk
Veracyte Q2 EPS $(0.12) Beats $(0.14) Estimat...
Benzinga Newsdesk
Earnings Scheduled For August 8, 2023
Benzinga Insights
Tuesday, August 01, 2023
Veracyte, Inc. Announces Study Published In JNCI Cancer Spectrum Demonstrates Real-World Utility Of Co's Decipher Prostate Genomic Classifier In Prostate Cancer Treatment
Happy Mohamed
Tuesday, July 25, 2023
Director At This Health Care Company Sells $118K of Stock
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
